Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

MEDVidi vs Nucific

MEDVidi
Graded #384

Higher grade

vs+1.7999999999999972
Nucific
Graded #417

Lower grade

The verdict

MEDVidi takes it — 58/100 to 56.2/100, but only just.

MEDVidi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MEDVidi is a US telehealth platform whose licensed providers evaluate patients and prescribe GLP-1 weight-management medications, including brand-name Zepbound (tirzepatide) and Wegovy (semaglutide), plus… Nucific is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
45
45
Dose & formulationEven
53
53
Clinical oversightMEDVidi +1
77
76
Labs & monitoringMEDVidi +10
62
52
FulfillmentNucific +8
59
67
Contract termsMEDVidi +14
55
41
MEDVidi · left barNucific · right bar

The numbers

MetricMEDVidiNucific
WeighScore58/10056.2/100
GradeCC
Scorecard rank#384#417
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
MEDVidi

Graded #384 · C

Strengths

  • Licensed providers can prescribe brand-name Zepbound and Wegovy
  • Transparent flat consultation fees (195 dollar initial, 159 dollar follow-up)
  • Prescriptions sent to the patient's pharmacy of choice, so insurance can be used

Where it loses points

  • Consult-fee model: medication is not included and its cost is separate
  • No medication pricing is published
  • State list is shown as a map rather than enumerated
Nucific

Graded #417 · C

Strengths

  • Founder is named and credentialed: Dr. Amy Lee, MD, triple board-certified in Internal Medicine, Obesity Medicine and Clinical Nutrition
  • Cites SURMOUNT-1 properly, naming the trial, the 20.9% average and the Jastreboff NEJM 2022 source
  • Discloses that featured patients were compensated for their time
  • Labels its NAD+ decline chart as illustrative and not a measurement, with an unusually careful methodology note
  • Offers compounded, microdosed and brand-name Ozempic and Zepbound in one catalogue

Where it loses points

  • No price is published anywhere; every option is gated behind a three-minute quiz
  • The LegitScript badge is a self-hosted image with generic alt text rather than the issued embed, so the certification could not be verified
  • A BBB Accredited A+ claim is displayed without a link to the BBB profile
  • No state list and no named pharmacy, only licensed U.S. pharmacies
  • Before-and-after photographs are used alongside compensated testimonials

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard